Breakthrough in hemophilia A treatment: Sobi’s ALTUVOCT receives EU marketing authorization

FHS
June 22, 2024
6:24 am

Sobi® today announced the European Commission has granted Marketing Authorization for ALTUVOCT™ (efanesoctocog alfa), for the treatment and prevention of bleeds and perioperative prophylaxis in hemophilia A. ALTUVOCT is a high-sustained factor VIII replacement therapy for all ages and any disease severity.

Ideaya showcases proof-of-concept data in a boost to synthetic lethality play

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

July 9, 2024

The new NIH director is walking a tightrope on Biden’s drug pricing vision

WASHINGTON — President Biden has promised to require fair prices from drugmakers that use federally funded research — and now, in a major recent move,

January 16, 2024

SciBase and Skin and Cancer Institute Collaborate to Advance AI-Driven Skin Cancer Detection in California

What You Should Know: SciBase Holding AB, a developer of augmented intelligence-based solutions for skin disorders, has entered into a collaboration agreement with the Skin

November 17, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.